Cover |
Jun. 02, 2022 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Amendment Description | On June 2, 2022, Aptose Biosciences, Inc. (the “Company”) issued a press release (the “Original Press Release”) announcing highlights from a corporate update and KOL event and filed a Current Report on Form 8-K furnishing the press release as Exhibit 99.1. On June 2, 2022, the Company issued an updated press release to correct language about responses and remissions of its lead drug candidate HM43239, which now reads eight total responses, including seven CRs and one PR, and favorable safety achieved at three separate dose levels (80 mg, 120 mg, 160 mg), which was incorrectly published as eight CRs and favorable safety achieved at three separate dose levels (80 mg, 120 mg, 160 mg). The Company is filing this amended Form 8-K to furnish the updated press release. Except as described above, all other information in the Original Press Release remains unchanged. |
| Document Period End Date | Jun. 02, 2022 |
| Entity File Number | 001-32001 |
| Entity Registrant Name | Aptose Biosciences Inc. |
| Entity Central Index Key | 0000882361 |
| Entity Tax Identification Number | 98-1136802 |
| Entity Incorporation, State or Country Code | Z4 |
| Entity Address, Address Line One | 251 Consumers Road |
| Entity Address, Address Line Two | Suite 1105 |
| Entity Address, City or Town | Toronto |
| Entity Address, State or Province | ON |
| Entity Address, Country | CA |
| Entity Address, Postal Zip Code | M2J 4R3 |
| City Area Code | 647 |
| Local Phone Number | 479-9828 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Shares, no par value |
| Trading Symbol | APTO |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |